Assessment Status |
NCPE assessment ongoing |
HTA ID |
22044 |
Drug |
Tisagenlecleucel |
Brand |
Kymriah® |
Indication |
For the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy. |
Rapid review commissioned |
28/06/2022 |
Rapid review completed |
27/07/2022 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of tisagenlecleucel compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE |
31/08/2022 |
Pre-submission consultation with Applicant |
06/12/2022 |
Full submission received from Applicant |
14/07/2023 |
Preliminary review sent to Applicant |
06/02/2024 |
NCPE assessment re-commenced |
08/03/2024 |
Follow-up to preliminary review sent to Applicant |
11/04/2024 |
NCPE assessment re-commenced |
18/04/2024 |